Bluebird Bio, Inc. BLUE
We take great care to ensure that the data presented and summarized in this overview for bluebird bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BLUE
View all-
Black Rock Inc. New York, NY15.4MShares$76.7 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.67MShares$23.2 Million0.02% of portfolio
-
Colony Group LLC Boston, MA41.9KShares$208,4510.0% of portfolio
-
Connacht Asset Management LP New York, NY31.6KShares$157,2200.59% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL28.7KShares$142,6880.0% of portfolio
-
Cutler Group LP800Shares$3,9760.0% of portfolio
-
Wipfli Financial Advisors Llc,554Shares$2,7530.0% of portfolio
-
Column Capital Advisors, LLC420Shares$2,0870.0% of portfolio
-
Halpern Financial, Inc. Ashburn, VA300Shares$1,4910.0% of portfolio
-
Private Capital Group, LLC246Shares$1,2220.0% of portfolio
Latest Institutional Activity in BLUE
Top Purchases
Top Sells
About BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at BLUE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2025
|
Joseph Vittiglio Chief Business & Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,625
-100.0%
|
-
|
|
Jun 02
2025
|
Joseph Vittiglio Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jun 02
2025
|
John O Agwunobi |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Najoh Tita Reid |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Richard A Colvin Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,666
-100.0%
|
-
|
|
Jun 02
2025
|
Richard A Colvin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jun 02
2025
|
Mark Vachon |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Andrew Obenshain President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
24,120
-100.0%
|
-
|
|
Jun 02
2025
|
Andrew Obenshain President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
14,820
+50.0%
|
-
|
|
Jun 02
2025
|
Elisabeth Leiderman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
O. James Sterling Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,500
-100.0%
|
-
|
|
Jun 02
2025
|
O. James Sterling Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jun 02
2025
|
Thomas J Klima |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,964
-100.0%
|
-
|
|
Jun 02
2025
|
Thomas J Klima |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jun 02
2025
|
Charlotte Jones Burton |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Nick Leschly |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Michael Cloonan |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,867
-100.0%
|
-
|
|
Jun 02
2025
|
Richard A. Paulson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,323
-100.0%
|
-
|
|
May 30
2025
|
Joseph Vittiglio Chief Business & Legal Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,143
-26.78%
|
-
|
|
May 30
2025
|
John O Agwunobi |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,323
-51.52%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 617K shares |
|---|
| Sale (or disposition) back to the issuer | 61.5K shares |
|---|---|
| Disposition due to a tender of shares in a change of control transaction | 45.9K shares |
| Open market or private sale | 42.3K shares |